Everything you need to need to know about the largest NYC startup funding rounds of February 2021; broken down by industry, stage, investors, and more…
The immune system at its core is a complex system of cells, organs, and tissues. These components work in unison to fight infection in the form of microbes. Developing an understanding of how this intricate system works is critical in ensuring that society as a whole has adequate immune health to combat disease and infection. Immunai has built the largest database for immunology in the world using machine learning and AI to map the entire immune system at a granular and specific level. This data can be leveraged by the healthcare industry to provide better therapeutics that get to market faster. This understanding will also allow biotech companies and pharmaceutical manufacturers to radically personalize therapeutics in the future. Immunai is initially focused on the oncology market but the offering is versatile can be applied to things like autoimmune disorders and infectious diseases like COVID-19. AlleyWatch caught up with CEO and Cofounder Noam Solomon to learn more about the impact that Immunai is having in the understanding of the immune system, the company’s partnerships, experience fundraising during the pandemic, and latest funding round from investors that include Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, Dexcel Pharma, Viola Ventures, and TLV Partners.
The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 2/12/2021 featuring funding details for Capitalize, Immunai, and much more. This page will be updated throughout the day to reflect any new fundings.